How Is Chronic Urticaria Treated When Antihistamines Are Not Enough? The Next Steps Explained

The second tube of antihistamine tablets is empty, the pharmacist has stopped asking why, and the welts are back on your forearms before breakfast. Nobody warned you that hives could become a nine-month relationship. You have stopped wearing short sleeves to work; you have started photographing your skin at 2 a.m. so a doctor will believe you.

This is the point at which many people type “chronic urticaria antihistamines not enough” into a search bar, half expecting to be told to try yet another over-the-counter brand. The honest answer is more interesting. Dermatology and allergy guidelines have, for several years, laid out a clear second and third rung of treatment for exactly this situation, and the evidence behind those rungs is reasonably strong.

What follows is a plain-language walk through that pathway: why antihistamines sometimes stall, what the next options actually do inside the skin, who is usually offered them, and what the first weeks tend to look like. Every decision along the way belongs to you and your treating clinician; this article is here to make the conversation easier.

What chronic urticaria actually is, and why the six-week mark matters

Urticaria is the medical name for hives: raised, itchy welts (wheals) that appear because tiny blood vessels in the skin leak fluid into the surrounding tissue. A single wheal usually fades within 24 hours, often leaving no trace, while new ones keep surfacing elsewhere. Roughly four in ten people with the chronic form also experience angioedema, a deeper swelling of the lips, eyelids, hands or feet, according to the international EAACI/GA²LEN urticaria guideline.

The line between “acute” and “chronic” is drawn at six weeks. If wheals have been coming and going, most days, for longer than that, clinicians use the term chronic urticaria. The NHS and Mayo Clinic both describe chronic hives as lasting months or, in some people, years.

Within that label sit two broad groups. Chronic spontaneous urticaria (CSU) means the wheals appear without an obvious external cause; it accounts for the majority of chronic cases. Chronic inducible urticaria means a specific physical stimulus reliably triggers wheals: pressure, cold, heat, sunlight, friction, exercise or vibration. Many people have a mix of both.

Why does the distinction matter for treatment? Because the pathway when antihistamines are not enough is built largely around CSU, and some inducible forms respond differently. A clinician who knows which type you have can predict more accurately which next step is likely to help.

One reassurance is worth stating early: chronic urticaria is rarely a sign of a hidden serious disease. The guideline recommends only a limited set of blood tests at diagnosis, and extensive searches for a cause are discouraged because they seldom change management. The frustration of chronic hives is real, but the condition itself is usually confined to the skin.

Why antihistamines stop being enough for chronic urticaria: what is happening in the skin

To understand why a tablet that worked in month one can falter by month six, it helps to look at the cell at the center of the story. Mast cells sit in the skin like tiny sentries packed with histamine and other inflammatory chemicals. When something tells them to fire, they release that cargo, blood vessels dilate and leak, nerves register itch, and a wheal rises.

Second-generation antihistamines (the non-drowsy type sold for allergies) do not stop the mast cell from firing. They block the H1 receptor, the docking site histamine uses to act on blood vessels and nerves. Think of it as padding the target rather than disarming the archer.

In chronic spontaneous urticaria, the archer is often overactive for internal reasons. About half of people with CSU carry autoantibodies, immune proteins that mistakenly bind to the mast cell’s IgE receptor and trigger release, a mechanism described by Cleveland Clinic and the international guideline. Mast cells also release mediators other than histamine, including leukotrienes, platelet-activating factor and cytokines, which an H1 blocker cannot touch.

So when antihistamines “stop working,” the usual explanation is not tolerance in the way people picture it. The drug still blocks histamine as well as it ever did; the disease has simply outgrown a histamine-only strategy. The guideline notes that a substantial share of people with CSU, roughly half, are not adequately controlled on a standard antihistamine regimen, which is precisely why a structured second line exists.

Two practical points flow from this. First, taking the antihistamine regularly rather than only when wheals appear matters, because the receptors need to be occupied before histamine arrives. Second, swapping between brands that contain the same class of molecule rarely changes the picture, which is why clinicians look upstream to the mast cell itself.

How is chronic spontaneous urticaria managed? The guideline pathway in plain language

The international urticaria guideline, endorsed by European and Asia-Pacific allergy and dermatology societies and summarized in the Mayo Clinic and NHS patient pages, describes management as a staircase with a simple aim: complete control of symptoms with the fewest medicines possible. Each step is reviewed on a timetable rather than left to drift.

Step one is a modern, non-sedating H1 antihistamine taken every day. If control is incomplete, the prescriber may adjust how that antihistamine is used within the licensed limits set by the guideline; this adjustment is a clinical decision and is not something to attempt on your own.

Step two, for people still not controlled, is omalizumab, an injectable biologic that binds free IgE and reduces the number of IgE receptors on mast cells. Step three, for those who do not respond adequately to the biologic, is cyclosporine, an oral immunosuppressant used off-label for urticaria under specialist monitoring.

Short courses of oral corticosteroids are reserved for severe flares and are not a maintenance treatment, because the side-effect burden grows quickly with prolonged use. Leukotriene receptor antagonists, which block a different mast-cell mediator, were part of older versions of the pathway and are still used by some clinicians, though the current guideline grades the evidence as weaker.

The pathway also runs in reverse. The guideline recommends periodically reassessing whether treatment can be reduced, because chronic spontaneous urticaria does remit on its own in many people over one to five years. A clinician will typically use two short questionnaires to judge where you sit: the Urticaria Activity Score over seven days (UAS7), which combines daily wheal count and itch, and the Urticaria Control Test (UCT). Scores, not impressions, decide when to step up and when to step back.

Before stepping up: what clinicians check when hives are not responding to antihistamines

A good consultation for antihistamine-resistant hives begins with questions, not a prescription pad. Several things can make a treatment appear to fail when the real problem lies elsewhere, and the guideline asks clinicians to rule these out first.

Timing and consistency come first. Antihistamines taken only after wheals appear are fighting a battle already lost; daily, preventive use is the baseline. Dosing instructions are individual, so the point is adherence, not numbers.

Next is the medicine cabinet. Non-steroidal anti-inflammatory painkillers (the ibuprofen and aspirin family) worsen wheals in a meaningful minority of people with CSU, and some blood-pressure medicines in the ACE-inhibitor class can cause angioedema that mimics urticaria. Your clinician will want a full list, including supplements.

Then comes the diary. Photographs with timestamps, a note of what you were doing, wearing or eating, and whether pressure, heat or cold preceded the wheals help separate spontaneous from inducible urticaria. If a physical trigger is suspected, a provocation test (for example, gently stroking the skin to check for dermographism, or applying an ice cube for cold urticaria) may be performed in clinic.

Blood tests are deliberately limited. The guideline suggests a full blood count, inflammatory markers and, in some settings, thyroid tests and total IgE; large allergy panels are discouraged because true food or inhalant allergy is an uncommon cause of chronic hives.

Finally, the clinician scores disease activity. A baseline UAS7 or UCT provides the yardstick against which the next step will be judged. Without it, “a bit better” is impossible to interpret. Only after this groundwork does the conversation move to a biologic or an immunosuppressant, and by then both you and the prescriber know exactly what success would look like.

Second-line treatment for chronic urticaria: what the biologic option actually does

Omalizumab is the first medicine the guideline recommends when antihistamines are not enough, and it is worth understanding why it earned that position. It is a monoclonal antibody, a laboratory-made immune protein designed to lock onto one target. Its target is IgE, the antibody that sits on mast cells and, when cross-linked, tells them to release their contents.

By mopping up free IgE in the blood, omalizumab lowers the amount available to coat mast cells. Over a few weeks, the cells respond by reducing the number of IgE receptors on their surface, which makes them markedly harder to trigger. This is why the drug can help even in people whose urticaria is driven by autoantibodies rather than classic allergy: fewer receptors means fewer places for those autoantibodies to act.

It is given as a subcutaneous injection, usually in a clinic at first, on a schedule the prescriber sets. Mayo Clinic notes that many people see improvement within the first weeks, while others need several injections before judging the response. The guideline advises continuing for a defined trial period before concluding that it has not worked, and it describes a group of slower responders who improve only after a longer course.

The safety profile is well characterized from years of use in asthma. Injection-site reactions and headache are the most common issues; anaphylaxis is rare but documented, which is why initial injections are observed. The drug does not broadly suppress the immune system, so the infection risk associated with immunosuppressants does not apply in the same way.

Whether omalizumab is appropriate, for how long, and what counts as an adequate response are decisions for the prescribing specialist, who will weigh your scores, your other conditions and your preferences. Newer biologics and oral agents are discussed later in this article.

Comparing the next-step options side by side

People often ask for a single table that lays out the choices beyond antihistamines. The one below summarizes what the international guideline and the cited patient resources describe; it is a map, not a menu. The right option depends on how active the disease is, what else you take, kidney and blood-pressure health, pregnancy plans and local availability, all of which your treating team will weigh.

Option	How it works	Where it sits in the pathway	Typical timeline to judge response	Main things monitored
Non-sedating H1 antihistamine (daily)	Blocks histamine’s receptor on vessels and nerves	First line	Weeks, reviewed with UAS7 or UCT	Adherence, drowsiness, interactions
Omalizumab (anti-IgE biologic)	Removes free IgE, reduces mast-cell receptors	Second line	Weeks to a few months; slow responders exist	Injection reactions, rare anaphylaxis
Cyclosporine (immunosuppressant, off-label)	Dampens T-cell and mast-cell activation	Third line, specialist only	Weeks; used for limited periods	Blood pressure, kidney function, infections
Short oral corticosteroid course	Broad anti-inflammatory effect	Rescue for severe flares only	Days	Sleep, mood, glucose; avoid prolonged use
Leukotriene receptor antagonist	Blocks a non-histamine mast-cell mediator	Add-on in some practices; weaker evidence	Weeks	Mood changes reported in some users

Two patterns stand out. First, the medicines with the strongest evidence in antihistamine-resistant chronic urticaria are the ones that act on the mast cell itself rather than on histamine alone. Second, every option carries a monitoring plan; nothing on this list is a “take it and forget it” treatment. That is not a reason for alarm, simply a reminder that stepping up is a partnership with a prescriber who checks in on a schedule.

Who is usually offered step-up treatment, and who is asked to wait

The guideline’s threshold for moving beyond antihistamines is clinical rather than arbitrary: persistent wheals or angioedema that remain uncontrolled, as measured by a validated score, after an adequate trial of a daily antihistamine used as prescribed. People in that group, especially those whose sleep, work or mood is being eroded, are the ones most often offered the biologic step.

A few situations typically prompt a clinician to pause before escalating. If the antihistamine has only been used intermittently, a period of consistent daily use is usually tried first. If NSAIDs or another suspected aggravating medicine are in the picture, those are reviewed. If the pattern suggests an inducible urticaria, trigger avoidance and specific strategies are explored alongside, because some inducible forms respond less predictably to the biologic.

Pregnancy and breastfeeding call for a careful conversation. Certain antihistamines have long safety records in pregnancy, while data for biologics are more limited and cyclosporine requires particular caution; the prescriber will weigh disease severity against the available evidence rather than applying a blanket rule.

Children can develop chronic urticaria too, and the same stepwise logic applies in principle, though licensing ages and dosing are specialist matters and sit entirely with the pediatric team.

People with kidney disease, uncontrolled high blood pressure or recurrent infections are generally steered away from cyclosporine or monitored more intensively if it is used. Those who have had a severe allergic reaction to a biologic in the past will be assessed individually.

Being “asked to wait” is rarely a dismissal. More often it reflects the guideline’s insistence that each rung be tested properly before the next, so that if the biologic is started, both you and your clinician can be confident the improvement is real and attributable.

What the following weeks usually look like after stepping up

Expect the first weeks after a treatment change to feel like data collection rather than transformation. Your clinician will likely ask you to keep scoring: a daily wheal count and itch rating for the UAS7, or the four-question UCT at each visit. Keeping the diary honestly, including bad days, is the most useful thing you can do in this phase.

If a biologic has been started, the first injection is usually followed by an observation period in clinic because of the small anaphylaxis risk; later doses may be given at home in some health systems, depending on local policy and the prescriber’s judgment. Mayo Clinic notes that improvement often begins within the first weeks, but the guideline explicitly describes slower responders who take several months, so a quiet first month is not a verdict.

Antihistamines are usually continued alongside the biologic initially. Whether and when they can be tapered is a decision the prescriber makes once control is stable, often guided by a run of low UAS7 scores.

For cyclosporine, the early weeks involve blood tests and blood-pressure checks on a schedule, because the kidneys are the organ the drug is most likely to strain. Improvement, when it occurs, tends to appear within weeks, and the guideline recommends keeping courses time-limited.

A short steroid course for a severe flare acts within days, which can be a relief, but it is followed by a planned stop; the guideline is clear that steroids are not a long-term strategy for chronic urticaria.

Throughout, remission remains possible. CSU resolves spontaneously in many people within one to five years, which is why the guideline asks clinicians to revisit the need for each medicine at intervals rather than assuming treatment is forever.

Can stress trigger hives? What the evidence actually shows

Ask a room of people with chronic urticaria whether stress makes it worse and most hands go up. Ask a room of researchers whether stress causes it and the answer is more careful. The honest position, reflected in Harvard Health’s guidance on chronic hives, is that stress is a recognized aggravating factor rather than a root cause.

The mechanism is plausible. Stress hormones and nerve signals can lower the threshold at which mast cells release their contents, and skin nerves themselves release peptides that nudge mast cells toward firing. Poor sleep, which travels with stress, independently increases itch perception. None of this means the hives are “in your head”; it means the skin and nervous system share wiring.

What the evidence does not support is the idea that fixing stress alone will switch chronic spontaneous urticaria off. The autoimmune and mast-cell mechanisms described earlier continue regardless of how calm a given week is. People sometimes delay stepping up treatment while they “work on stress,” and the guideline’s structure argues against that delay when scores remain high.

The practical middle ground is to treat stress as one dial among several. Regular sleep, limiting alcohol (a known aggravator in some people), and simple relaxation practices are low-risk and may reduce flare frequency for some, as Harvard Health notes. If anxiety or low mood is significant, that deserves its own care; chronic itch is a well-documented driver of both, and treating the skin often improves the mind as much as the reverse.

A useful question to put to your clinician is whether your flare pattern tracks stressful periods on your diary. If it does, that information shapes supportive advice; if it does not, it saves you from chasing a trigger that is not yours.

What causes hives around the waistband? Pressure, friction and inducible urticaria

Welts that bloom exactly where a belt, bra strap or sock elastic sits are one of the most common patterns people report, and they usually point to one of two inducible forms of urticaria rather than to an allergy to the fabric.

The first is symptomatic dermographism, sometimes called skin writing. Light friction or stroking is enough to raise a wheal within minutes, which fades within an hour or so. A clinician can confirm it by drawing a blunt object across the skin and watching the line swell. It is the most common inducible urticaria and often coexists with CSU.

The second is delayed pressure urticaria. Here, sustained pressure (a waistband worn all day, a heavy bag strap, sitting on a hard chair) produces deeper, sometimes painful swelling that appears hours later and can last beyond a day. Because of the delay, people often blame the wrong activity.

Neither pattern is caused by detergent or fabric in most cases, although genuine contact dermatitis from rubber or metal fasteners exists and looks different (scaly, more eczema-like, confined to the contact area).

Managing inducible urticaria relies partly on mechanics: looser waistbands, soft-edged clothing, avoiding tight straps on affected days. Harvard Health’s practical list for chronic hives includes exactly this kind of wardrobe adjustment. Antihistamines remain the medical first line, and the guideline notes that dermographism often responds to them; delayed pressure urticaria is more stubborn and is one of the forms in which clinicians may consider the biologic step after antihistamines fail.

Describing precisely where and when your waistband wheals appear, with photos, helps your clinician distinguish friction from pressure, and that distinction changes the advice.

What medicine to take for urticaria? Why the answer depends on your prescriber

Search engines are full of lists promising the “best” hive medicine. The honest answer is that the right medicine for chronic urticaria depends on your type of urticaria, your activity score, what you have already tried, your other health conditions and whether you are pregnant or breastfeeding. That is not evasion; it is how the guideline is written.

What can be said in general terms is the order of play. Non-sedating second-generation H1 antihistamines are the first-line class, chosen over older sedating types because they do not impair driving or sleep architecture and have fewer interactions. Within that class, several generic molecules exist, and the choice between them is largely individual.

When that class is not enough, the next guideline-backed step is the anti-IgE biologic, and after that an immunosuppressant. Oral corticosteroids are rescue, not routine. Topical creams, including steroid creams, have little role in urticaria because the problem originates in deeper mast cells rather than on the surface; cooling lotions can soothe itch but do not change the course.

A few newer agents deserve a mention because people will read about them. Monoclonal antibodies that block the interleukin-4 and interleukin-13 pathway, developed for eczema, have been studied in CSU, and oral drugs that inhibit Bruton tyrosine kinase, an enzyme mast cells use to fire, have shown promising trial results and are becoming available in some countries. Their place in routine pathways is still being defined, and the guideline’s current recommendation remains the sequence above.

Nothing in this section is a prompt to start, stop or swap a medicine on your own. The point is to arrive at the appointment knowing the structure, so that “what should I take?” becomes “which step am I on, and what would move me to the next one?”

What people often get wrong about antihistamine-resistant chronic urticaria

Chronic hives attract more folklore than most skin conditions, partly because the wheals move and the cause is invisible. Clearing a few myths saves time and, sometimes, money.

Myth one: “I must be allergic to something.” In chronic spontaneous urticaria, a true allergen is rarely found, and the guideline discourages wide allergy panels for this reason. Elimination diets without clinical direction tend to produce weight loss and frustration rather than clear skin.

Myth two: “My body has become tolerant to antihistamines.” As explained earlier, the receptor block still works; the disease has shifted toward mechanisms histamine blockade cannot reach. Switching between products in the same class seldom helps.

Myth three: “Steroids fix it, so I should stay on them.” Steroids calm flares fast, but the guideline is unambiguous that prolonged use trades a skin problem for bone, glucose, blood-pressure and mood problems. They are a bridge, not a destination.

Myth four: “Biologics are a last resort for desperate cases.” In the current pathway the anti-IgE biologic is the second step, not the fifth, and it is used in people whose daily life is being disrupted, not only in extreme disease.

Myth five: “Chronic means permanent.” Many people remit within one to five years. The word describes duration beyond six weeks, not a life sentence.

Myth six: “Natural remedies are safer than prescriptions.” Supplements marketed for hives lack good evidence, and some interact with prescription medicines; the NIH Office of Dietary Supplements is a sober place to check claims.

Myth seven: “If one doctor could not help, none can.” The pathway exists precisely for people who have stalled; asking for a referral to a dermatologist or allergist with urticaria experience is a reasonable request.

Day-to-day habits that support treatment while the medicines do their work

No lifestyle measure replaces the pathway above, but several low-risk habits make flares easier to live with and give your clinician cleaner data.

Keep the skin cool. Heat dilates vessels and worsens itch, so lukewarm showers, light bedding and a cool bedroom help, a point Harvard Health makes in its list of practical relief measures. A refrigerated, fragrance-free moisturizer or a cool compress can settle an itchy patch without medication.

Dress for the condition. Loose, soft clothing matters most for people with dermographism or pressure urticaria, as discussed in the waistband section. Avoid tight straps on days when you will be carrying a bag or sitting for hours.

Watch the known aggravators. NSAID painkillers, alcohol and, for some, spicy food or overheating during exercise can lower the mast-cell threshold. Noting these in your diary lets you and your clinician decide whether they are relevant to you rather than avoiding everything on principle.

Protect sleep. Itch peaks at night for many people because skin temperature rises and distraction falls. Consistent bedtimes, a cool room and discussing night-time itch with your prescriber are more effective than scrolling at 2 a.m. with a bag of frozen peas.

Score, do not guess. Filling in the UAS7 daily or the UCT weekly takes under two minutes and turns a vague “it’s been bad” into a number that can justify a step up or support a step down.

Mind the mind. Chronic itch wears on mood and concentration, and acknowledging that to your clinician is not weakness; it is part of the picture the guideline asks them to assess when weighing how urgently to escalate.

Questions to ask your care team about the next step

Appointments for chronic urticaria are short and the pathway has several branches, so arriving with questions makes the time count. These are the ones that tend to unlock the most useful answers.

• Which type of chronic urticaria do you think I have, spontaneous, inducible or both, and how does that shape the plan?
• What is my current activity or control score, and what score would prompt you to move to the next step?
• Am I using my antihistamine the way the guideline intends, and is there anything about timing or consistency you would change?
• Are any of my other medicines or supplements likely to be aggravating the wheals?
• If we move to the biologic, how will the first injections be supervised, how long will we trial it before judging the response, and what would “not working” look like?
• If an immunosuppressant is considered, what monitoring will I need and for how long?
• What is the plan for severe flares, and how do I avoid relying on repeated steroid courses?
• How often will we review whether treatment can be reduced, given that this condition can remit?
• Are there newer treatments you are watching, and would I be a candidate if they become available here?
• Who do I contact between appointments if the plan is not working or something frightens me?

Write down the answers, including the scores, and bring them to the next visit. The guideline’s pathway works best when both sides are tracking the same numbers over time. If an answer is “we don’t know yet,” that is a legitimate response in a condition with unpredictable timing; the useful follow-up is “when will we know, and what will we check?”

When to call your doctor: red-flag signs with chronic urticaria

Most chronic urticaria is uncomfortable rather than dangerous, but a few situations need prompt attention, and knowing them in advance removes guesswork at the worst moment.

Call emergency services immediately if wheals or swelling are accompanied by difficulty breathing, wheezing, tightness in the throat, trouble swallowing, a hoarse voice, dizziness or fainting. These can indicate anaphylaxis or airway angioedema, and the NHS and Mayo Clinic both class them as emergencies regardless of how long you have had hives.

Contact your doctor the same day if swelling involves the tongue, lips or face and is progressing, even without breathing difficulty; if you develop fever, joint pain or feel generally unwell alongside the wheals; if individual wheals last longer than 24 hours, are painful rather than itchy, or leave bruising behind, since this pattern can suggest urticarial vasculitis, an inflammation of small blood vessels that needs different assessment; or if you have started a new treatment and notice an unexpected reaction such as spreading rash, chest discomfort or marked swelling at an injection site.

Book a routine appointment if your activity or control scores are climbing despite taking treatment as prescribed, if you are needing repeated steroid courses, if itch is wrecking sleep or mood, or if you are planning a pregnancy and want to review your medicines in advance.

Finally, call if you simply feel the plan has stalled. The guideline builds in review points precisely so that people are not left on an ineffective step for months. Every escalation, de-escalation and investigation described in this article is a decision for your treating team; your role is to bring the scores, the photos and the questions that let them make it well.

Frequently asked questions

What is the next step when chronic urticaria antihistamines are not enough?

The guideline-recommended next step is omalizumab, an injectable anti-IgE biologic, after the prescriber has confirmed the antihistamine is being used daily as intended and reviewed aggravating medicines. If the biologic does not achieve control over a defined trial period, a specialist may consider cyclosporine. Each move is based on validated activity scores and sits with the treating team.

How is chronic spontaneous urticaria managed in the long term?

Management follows a staircase: daily non-sedating antihistamine, then a biologic, then an immunosuppressant, with short steroid courses only for severe flares. Clinicians track control with the UAS7 and UCT scores and review at intervals whether treatment can be reduced, because chronic spontaneous urticaria often remits on its own within one to five years.

Can stress trigger hives, or is that a myth?

Stress is a recognized aggravating factor rather than the underlying cause. Stress hormones and skin nerve signals lower the threshold at which mast cells release histamine, so flares often cluster around difficult weeks. Managing stress and sleep can reduce flare frequency for some people, but it does not replace the medical pathway when activity scores remain high.

What causes hives around the waistband specifically?

Waistband wheals most often reflect inducible urticaria: dermographism, where friction raises a wheal within minutes, or delayed pressure urticaria, where sustained pressure causes deeper swelling hours later. Fabric allergy is rarely the explanation. Looser clothing helps, antihistamines are first line, and stubborn pressure urticaria may be considered for the biologic step.

What medicine to take for urticaria if over-the-counter tablets have stopped helping?

The answer depends on your urticaria type, activity score, pregnancy status and other conditions, which is why it must come from a prescriber. In general terms, the guideline moves from a daily non-sedating antihistamine to an anti-IgE biologic and then an immunosuppressant. Swapping between similar over-the-counter products rarely changes the outcome.

Why are my hives not responding to antihistamines any more?

The antihistamine is still blocking histamine; the disease has shifted toward mechanisms it cannot reach. In chronic spontaneous urticaria, about half of people have autoantibodies that trigger mast cells directly, and mast cells release leukotrienes and cytokines that H1 blockers do not affect. That is why treatments aimed at the mast cell itself form the next step.

How long does omalizumab take to work for chronic hives?

Many people notice improvement within the first weeks, but the international guideline describes slower responders who improve only after several months of injections. Prescribers therefore set a defined trial period before judging whether it has worked, and they measure response with activity scores rather than impressions. The exact schedule and duration are decided by the prescribing specialist.

Is second-line treatment for chronic urticaria safe?

The biologic has a well-characterized safety record from years of use; injection-site reactions and headache are the most common issues, and anaphylaxis is rare but monitored for. Cyclosporine requires regular blood-pressure and kidney checks and is used for limited periods. Both are prescribed and monitored by specialists who weigh risks against how much the urticaria is disrupting life.

Can I develop tolerance to antihistamines?

True pharmacological tolerance to second-generation antihistamines is not well supported by evidence. What people experience is usually the disease outgrowing a histamine-only approach, or inconsistent daily use leaving receptors unprotected when histamine is released. Rather than rotating products, the guideline directs clinicians to reassess activity scores and consider the next rung of the pathway.

Will chronic urticaria ever go away on its own?

Often, yes. Chronic spontaneous urticaria remits spontaneously in many people within one to five years, and some inducible forms also settle over time. Nobody can predict the timing for an individual, which is why guidelines ask clinicians to review at intervals whether treatment can be stepped down, rather than assuming medicines are needed indefinitely.

References

• NHS: Hives
• MedlinePlus: Hives

This article is for general information only and is not a substitute for professional medical advice. Please consult a qualified doctor about your individual situation.